Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy
Identifieur interne : 000127 ( Istex/Corpus ); précédent : 000126; suivant : 000128Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy
Auteurs : Bradley F. Boeve ; Michael H. Silber ; Tanis J. Ferman ; John A. Lucas ; Joseph E. ParisiSource :
- Movement Disorders [ 0885-3185 ] ; 2001-07.
English descriptors
- KwdEn :
Abstract
Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders. In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder. In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p < 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p < 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p < 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively. Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1120
Links to Exploration step
ISTEX:F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title><author><name sortKey="Boeve, Bradley F" sort="Boeve, Bradley F" uniqKey="Boeve B" first="Bradley F." last="Boeve">Bradley F. Boeve</name><affiliation><mods:affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Silber, Michael H" sort="Silber, Michael H" uniqKey="Silber M" first="Michael H." last="Silber">Michael H. Silber</name><affiliation><mods:affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Ferman, Tanis J" sort="Ferman, Tanis J" uniqKey="Ferman T" first="Tanis J." last="Ferman">Tanis J. Ferman</name><affiliation><mods:affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Lucas, John A" sort="Lucas, John A" uniqKey="Lucas J" first="John A." last="Lucas">John A. Lucas</name><affiliation><mods:affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Parisi, Joseph E" sort="Parisi, Joseph E" uniqKey="Parisi J" first="Joseph E." last="Parisi">Joseph E. Parisi</name><affiliation><mods:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1120</idno><idno type="url">https://api.istex.fr/document/F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title><author><name sortKey="Boeve, Bradley F" sort="Boeve, Bradley F" uniqKey="Boeve B" first="Bradley F." last="Boeve">Bradley F. Boeve</name><affiliation><mods:affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Silber, Michael H" sort="Silber, Michael H" uniqKey="Silber M" first="Michael H." last="Silber">Michael H. Silber</name><affiliation><mods:affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Ferman, Tanis J" sort="Ferman, Tanis J" uniqKey="Ferman T" first="Tanis J." last="Ferman">Tanis J. Ferman</name><affiliation><mods:affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Lucas, John A" sort="Lucas, John A" uniqKey="Lucas J" first="John A." last="Lucas">John A. Lucas</name><affiliation><mods:affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Parisi, Joseph E" sort="Parisi, Joseph E" uniqKey="Parisi J" first="Joseph E." last="Parisi">Joseph E. Parisi</name><affiliation><mods:affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="622">622</biblScope><biblScope unit="page" to="630">630</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6</idno><idno type="DOI">10.1002/mds.1120</idno><idno type="ArticleID">MDS1120</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Lewy body disease</term><term>dementia</term><term>parkinsonism</term><term>synuclein</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders. In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder. In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p < 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p < 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p < 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively. Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Bradley F. Boeve MD</name><affiliations><json:string>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</json:string></affiliations></json:item><json:item><name>Michael H. Silber MBChB</name><affiliations><json:string>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</json:string></affiliations></json:item><json:item><name>Tanis J. Ferman PhD</name><affiliations><json:string>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</json:string></affiliations></json:item><json:item><name>John A. Lucas PhD</name><affiliations><json:string>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</json:string></affiliations></json:item><json:item><name>Joseph E. Parisi MD</name><affiliations><json:string>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>synuclein</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Lewy body disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders.In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder.In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p > 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p > 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p > 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively.Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>2706</abstractCharCount><pdfWordCount>5513</pdfWordCount><pdfCharCount>36628</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>401</abstractWordCount></qualityIndicators><title>Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title><genre><json:string>Serial article</json:string></genre><host><volume>16</volume><pages><total>9</total><last>630</last><first>622</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1002/mds.1120</json:string></doi><id>F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2001</date></publicationStmt><notesStmt><note>National Institute on Aging - No. AG 16574; No. AG 06786; No. AG 15866;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title><author><persName><forename type="first">Bradley F.</forename><surname>Boeve</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Mayo Clinic, Department of Neurology, 200 First Street SW, Rochester, MN 55905</p></note><affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation></author><author><persName><forename type="first">Michael H.</forename><surname>Silber</surname><roleName type="degree">MBChB</roleName></persName><affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation></author><author><persName><forename type="first">Tanis J.</forename><surname>Ferman</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</affiliation></author><author><persName><forename type="first">John A.</forename><surname>Lucas</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</affiliation></author><author><persName><forename type="first">Joseph E.</forename><surname>Parisi</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07"></date><biblScope unit="vol">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="622">622</biblScope><biblScope unit="page" to="630">630</biblScope></imprint></monogr><idno type="istex">F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6</idno><idno type="DOI">10.1002/mds.1120</idno><idno type="ArticleID">MDS1120</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders.In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder.In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p < 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p < 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p < 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively.Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>parkinsonism</term></item><item><term>dementia</term></item><item><term>synuclein</term></item><item><term>Lewy body disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-03-16">Received</change><change when="2001-01-10">Registration</change><change when="2001-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v16:4</doi><numberingGroup><numbering type="journalVolume" number="16">16</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2001-07">July 2001</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="6" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.1120</doi><idGroup><id type="unit" value="MDS1120"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2001 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2000-03-16"></event><event type="manuscriptRevised" date="2001-01-09"></event><event type="manuscriptAccepted" date="2001-01-10"></event><event type="publishedOnlineEarlyUnpaginated" date="2001-06-15"></event><event type="firstOnline" date="2001-06-15"></event><event type="publishedOnlineFinalForm" date="2001-07-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">622</numbering><numbering type="pageLast">630</numbering></numberingGroup><correspondenceTo>Mayo Clinic, Department of Neurology, 200 First Street SW, Rochester, MN 55905</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1120.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="57"></count><count type="wordTotal" number="5365"></count></countGroup><titleGroup><title type="main" xml:lang="en">Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title><title type="short" xml:lang="en">RBD in Neurodegenerative Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Bradley F.</givenNames><familyName>Boeve</familyName><degrees>MD</degrees></personName><contactDetails><email>bboeve@mayo.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael H.</givenNames><familyName>Silber</familyName><degrees>MBChB</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Tanis J.</givenNames><familyName>Ferman</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>John A.</givenNames><familyName>Lucas</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Joseph E.</givenNames><familyName>Parisi</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">parkinsonism</keyword><keyword xml:id="kwd2">dementia</keyword><keyword xml:id="kwd3">synuclein</keyword><keyword xml:id="kwd4">Lewy body disease</keyword></keywordGroup><fundingInfo><fundingAgency>National Institute on Aging</fundingAgency><fundingNumber>AG 16574</fundingNumber><fundingNumber>AG 06786</fundingNumber><fundingNumber>AG 15866</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders.</p><p>In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder.</p><p>In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p < 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p < 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p < 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively.</p><p>Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>RBD in Neurodegenerative Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy</title></titleInfo><name type="personal"><namePart type="given">Bradley F.</namePart><namePart type="family">Boeve</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation><description>Correspondence: Mayo Clinic, Department of Neurology, 200 First Street SW, Rochester, MN 55905</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael H.</namePart><namePart type="family">Silber</namePart><namePart type="termsOfAddress">MBChB</namePart><affiliation>Sleep Disorders Center and Department of Neurology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tanis J.</namePart><namePart type="family">Ferman</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John A.</namePart><namePart type="family">Lucas</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry and Psychology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph E.</namePart><namePart type="family">Parisi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2001-07</dateIssued><dateCaptured encoding="w3cdtf">2000-03-16</dateCaptured><dateValid encoding="w3cdtf">2001-01-10</dateValid><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">57</extent><extent unit="words">5365</extent></physicalDescription><abstract lang="en">Our objective was to examine whether rapid eye movement (REM) sleep behavior disorder occurs in disproportionally greater frequency in multiple system atrophy (MSA), Parkinson's disease (PD), and dementia with Lewy bodies (DLB), collectively known as the synucleinopathies, compared to other nonsynucleinopathy neurodegenerative disorders. In study 1, we reviewed the clinical records of 398 consecutive patients evaluated at Mayo Clinic Rochester for parkinsonism and/or cognitive impairment. The frequency of suspected and polysomnogram (PSG)‐confirmed REM sleep behavior disorder (RBD) among subjects with the synucleinopathies MSA, PD, or DLB was compared to the frequency among subjects with the nonsynucleinopathies Alzheimer's disease (AD), frontotemporal dementia (FTD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), mild cognitive impairment (MCI), primary progressive aphasia (PPA), and posterior cortical atrophy (PCA). In study 2, we reviewed the clinical records of 360 consecutive patients evaluated at Mayo Clinic Jacksonville for parkinsonism and/or cognitive impairment. The frequency of probable RBD among patients with PD and DLB was compared to the frequency among patients with AD and MCI. In study 3, we reviewed the brain biopsy or postmortem autopsy diagnoses of 23 Mayo Clinic Rochester patients who had been clinically examined for possible RBD and a neurodegenerative disorder. In study 1, patients with MSA, PD, or DLB were more likely to have probable and PSG‐confirmed RBD compared to subjects with the nonsynucleinopathies (probable RBD 77/120=64% vs. 7/278=3%, p < 0.01; PSG‐confirmed RBD 47/120=39% vs. 1/278=0%, p < 0.01). In study 2, patients with PD and DLB were more likely to have probable RBD compared to those with AD and MCI (56% vs. 2%, p < 0.01). In study 3, of the 23 autopsied patients who had been questioned about possible RBD, 10 were clinically diagnosed with RBD. The neuropathologic diagnoses in these 10 included Lewy body disease in nine, and MSA in one. Of the other 13 cases, 12 did not have a history suggesting RBD, and the one case who did had normal electromyographic atonia during REM sleep on PSG and autopsy findings of PSP. Only one of these 13 had a synucleinopathy. The positive predictive values for RBD indicating a synucleinopathy for studies 1–3 were 91.7%, 94.3%, and 100.0%, respectively. Clinically suspected and PSG‐proven RBD occurs with disproportionally greater frequency in MSA, PD, and DLB compared to other neurodegenerative disorders. In the setting of degenerative dementia and/or parkinsonism, we hypothesize that RBD is a manifestation of an evolving synucleinopathy. © 2001 Movement Disorder Society.</abstract><note type="funding">National Institute on Aging - No. AG 16574; No. AG 06786; No. AG 15866; </note><subject lang="en"><genre>Keywords</genre><topic>parkinsonism</topic><topic>dementia</topic><topic>synuclein</topic><topic>Lewy body disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>622</start><end>630</end><total>9</total></extent></part></relatedItem><identifier type="istex">F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6</identifier><identifier type="DOI">10.1002/mds.1120</identifier><identifier type="ArticleID">MDS1120</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2001 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F1F6D6446583825F6CE95F25D924E0C4ECD9A9B6
|texte= Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy
}}
| This area was generated with Dilib version V0.6.23. |  |